Status:
UNKNOWN
Suprachoroidal Injection of Triamcinolone Acetonide for Management of Diabetic Macular Edema
Lead Sponsor:
Azza Mohamed Ahmed Said
Collaborating Sponsors:
Ain Shams University
Conditions:
Safety
Efficacy
Eligibility:
All Genders
40-70 years
Phase:
NA
Brief Summary
Intravitreal triamcinolone acetonide is a well-known method of treatment of diabetic macular edema, however, it has many side effects, most commonly causing cataract and glaucoma. Suprachoroidal route...
Detailed Description
The purposes of this study were: 1. To compare between intravitreal and suprachoroidalTA injection for treatment of DME in terms of improvement in both best corrected visual acuity (BCVA) and central...
Eligibility Criteria
Inclusion
- Type-II Diabetes Mellitus patients.
- Centrally involving DME with central thickness\<300µm with no vitreomacular traction.
- Recently diagnosed DME or received treatment for DME in more than six months.
Exclusion
- Pre-existingretinal disease other than diabetic retinopathy.
- Diabetic macular ischemia.
- IOP ≥ 21 mmHg and/or asymmetrical cup disc ratio or glaucoma patients.
- Prior cataract extraction of less than six months.
- Opaque media, uncooperative patients or patients with poor fixation.
- Any uncontrolled systemic disease.
- Systemic or local medicationsthat might affect the macular thickness
Key Trial Info
Start Date :
March 13 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 7 2021
Estimated Enrollment :
45 Patients enrolled
Trial Details
Trial ID
NCT04069780
Start Date
March 13 2019
End Date
August 7 2021
Last Update
September 3 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ain Shams University
Cairo, Egypt